About ZemairaWhat is Alpha-1?Patient SupportPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Living with Alpha-1Questions to ask your doctorNewly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Receive Zemaira at no charge for up to 2 weeks.

Already Treating Your Alpha-1?

As a diagnosed Alpha, you want to do all you can to stay healthy and prevent further lung damage. In addition to making lifestyle changes, you may need to be considering a number of therapeutic options.

We created Zemaira for chronic A1-PI augmentation therapy in adult Alpha-1 patients with emphysema. Zemaira has been shown to be safe and effective, with half or less the infusion volume and time of other Alpha-1 therapies.1-3*  What’s more, Zemaira is backed by patient support programs that provide you with peace of mind.

* Based on recommended dosage as stated in the product package inserts of 60 mg/kg body weight at the infusion rate of 0.08 mL/kg/min.

. . .with Zemaira, you can expect high purity, efficacy, safety, and convenience.

Living With Alpha-1
Maintaining your health involves lifestyle changes and medical care. Review the list of suggestions that can help keep you healthy.

Questions to Ask Your Doctor About Augmentation Therapy
These questions will help you and your doctor decide if Zemaira is the right therapy for you.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

  1. Prolastin® Alpha1-Proteinase Inhibitor (Human), Full Prescribing Information, March 2003.
  2. Aralast™ Alpha1-Proteinase Inhibitor (Human), Full Prescribing Information, January 2003.
  3. Data on file, CSL Behring LLC.